Point source concentration of GDNF may explain failure of phase II clinical trial.

@article{Salvatore2006PointSC,
  title={Point source concentration of GDNF may explain failure of phase II clinical trial.},
  author={Michael F Salvatore and Y. D. Ai and Brent Fischer and Amanda M Zhang and Richard C Grondin and Zhi-Ming Zhang and Greg A. Gerhardt and Don M. Gash},
  journal={Experimental neurology},
  year={2006},
  volume={202 2},
  pages={497-505}
}
Significant differences have been reported in results from three clinical trials evaluating intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) for the treatment of Parkinson's disease. To determine if problems in drug bioavailability could have contributed to the discrepancies between studies, we have analyzed the distribution of intraputamenally infused GDNF in the rhesus monkey brain using the delivery system and infusion protocol followed in a phase 2 clinical… CONTINUE READING

From This Paper

Topics from this paper.
86 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 86 extracted citations

Similar Papers

Loading similar papers…